- Home
- CURV vs OTLK Comparison
CURV vs OTLK Comparison
Compare CURV & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CURV | OTLK |
|---|---|---|
| Founded | 2001 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 259.7M | 249.6M |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | CURV | OTLK |
|---|---|---|
| Price | $2.34 | $0.87 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 4 |
| Target Price | $1.59 | ★ $2.50 |
| AVG Volume (30 Days) | 285.6K | ★ 12.6M |
| Earning Date | 06-04-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.91 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,000,092,000.00 | $8,146,123.00 |
| Revenue This Year | N/A | $1,430.98 |
| Revenue Next Year | $1.15 | $173.23 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.94 | $0.16 |
| 52 Week High | $2.86 | $3.39 |
Technical Indicators
Market Signals| Indicator | CURV | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 48.75 | 37.91 |
| Support Level | $1.03 | $0.75 |
| Resistance Level | $2.86 | $0.94 |
| Average True Range (ATR) | 0.16 | 0.14 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 17.60 | 17.23 |
Price Performance
Historical ComparisonAbout CURV Torrid Holdings Inc.
Torrid Holdings Inc is a direct-to-consumer brand in North America dedicated to offering a diverse assortment of stylish apparel, intimates, and accessories skillfully designed for curvy women. Its extensive collection features high-quality merchandise, including tops, bottoms, denim, dresses, intimates, activewear, footwear, and accessories. The company has one reportable segment, which includes the operation of its e-Commerce platform and stores.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.